The all-stock merger between Telaria and the Rubicon Project is highly complementary and liable to create the biggest sell-side platform in the market. The combined company will be very reasonably […]
The company’s fortunes, and those of its shareholders have greatly improved on the back of a host of new products and a revamping of its sales channels. While these positive […]
Stage Stores is converting all of its department stores to the off-price format next year, after having converted a number of stores already. With multiple things going on (sales, closures, […]
Teladoc Health is the market leader in the burgeoning virtual healthcare market, which is in the early innings of its growth trajectory. The company has multiple avenues for growth, not […]
Some temporary headwinds knocked Adesto shares well off the late summer’s highs. We think the fall is exaggerated, underneath the hood we find a healthy company with multiple avenues to […]
Austrian economics invariably predicts gloom and doom as a result of policy intervention, which by definition create “artificial” booms and bubbles. Events on the ground have forced even some of […]
The company was buffeted some temporary headwinds, a technical problem with the introduction of a new product and new contract moving out to Q4 and Q1. The temporary headwinds and […]
The shares have been a victim of a larger SaaS selloff and some temporary headwinds. We see the latter gradually lifting. While the shares are not cheap and, therefore, have […]
The company’s Cesium-131 based cancer treatments are effective, cheap and produce less side effects than other radiation. The company’s market cap is small in relation to its first big target […]
The company has a number of products in various stages of regulatory approval, one of which will start to generate revenue within 2-4 weeks. The company has finance lined up […]